Knight Therapeutics (Knight Therapeutics) EBIT per Share : $-0.09 (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics EBIT per Share?

Knight Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Knight Therapeutics's EBIT per Share or its related term are showing as below:

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Knight Therapeutics was 30.10% per year. The lowest was -54.10% per year. And the median was -14.75% per year.

KHTRF's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.25
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Knight Therapeutics's EBIT for the three months ended in Mar. 2024 was $-3.4 Mil.

Knight Therapeutics EBIT per Share Historical Data

The historical data trend for Knight Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics EBIT per Share Chart

Knight Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.13

0.21

0.07

-0.24

-0.07

Knight Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.01	0.02	0.08	-0.16	-0.03

Knight Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Knight Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.081	/	107.466
=	-0.07

Knight Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.374	/	101.173
=	-0.03

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09

Knight Therapeutics (OTCPK:KHTRF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Knight Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics (Knight Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (OTCPK:KHTRF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

GUD:Canada

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.